
Novartis Ventures et al. in £8.65m round for ITS
Novartis Ventures, Sweden’s HealthCap, France’s Truffle Capital and London Technology Fund, have participated in a £8.65m funding round for British biotech company Immune Targeting Systems (ITS).
Latest News
McDermott adds to German PE team with Noerr and Latham duo
Noerr’s Holger Ebersberger and Latham & Watkins’ Hanno Witt to join the firm’s Munich office
MML launches lower-mid-market strategy for UK, Northern European B2B assets
London-headquartered GP invested in AI provider MIcompany in first deal for new strategy this week
Revo Capital preps third fund for 2023 launch
VC firm aims to raise USD 75m-150m from private and public investors including blue-chip institutional LPs in Europe, MENA and US
Oakley raises EUR 2.85bn for fifth flagship fund
More than twice the size of its 2019 predecessor, the vehicle will allow for larger equity tickets, more investments and bolt-ons
Back to Top